1 active not recruiting. 1 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Early Phase 1 | 1 | Active not recruiting 1 |
Follow Tu Dan: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Ruxolitinib for Cancer Cachexia Identify any dose-limiting toxicity (DLT) when ruxolitinib is administered to NSCLC cachexia patients. - Stage IV Non-small Cell Lung Cancer, Cachexia | Early Phase 1 | Active not recruiting | Tu Dan | 10 | 2022-02-23 | 2026-07-07 |
Anorexia (1) · Cachexia (1) · Carcinoma, Non-Small-Cell Lung (1) · Lung Neoplasms (1) · Muscular Atrophy (1)
United States (1)